期刊文献+

联合氯法齐明方案治疗耐多药肺结核的临床研究 被引量:20

Clinical study of combination treatment with clofazimine and others for patients with multi-drug-resistant tuberculosis
下载PDF
导出
摘要 目的:探讨氯法齐明联合其他抗结核药物治疗耐多药肺结核的临床疗效。方法:72例耐多药肺结核患者,随机分为试验组32例和对照组40例,观察治疗6、18个月末痰结核菌阴转率、胸部X线病灶和空洞变化情况等。结果:治疗6个月末试验组的涂阳阴转率、培阳阴转率、病灶显吸率分别为81.3%、84.4%、37.5%,均高于对照组的57.5%、62.5%、15.0%,差异有统计学意义(P<0.05),其他结果2组无明显差异(P>0.05)。结论:联合氯法齐明方案治疗耐多药肺结核可以提高疗效、缩短疗程,特别是在强化期具有明显的优势。 AIM. To investigate the efficacy of combination treatment with clofazimine and other antituberculosis drugs for patients with multi-drug-resistant tuberculosis. METHODS: 72 cases with multi-drug-resistant tuberculosis were randomly divided into experimental group (n=32) and control group (n=40). The treat- ment effect was observed at the 6th month and 18th month after treatment. RESULTS. 6 months later, the sputum negtive conversion rate in smear and in culture were 81.3% and 84.4% respectively and the rate in X-rays focusabsorption was 37.5%in experimental group, which were significantly higher than those in control treatmen tients wi group. CONCLU t with clofazimine SION. Combination and others for pa th multi-drug-resistant improve the curative effect and s treatment especially in the stage tuberculosis can horten course of strengthened.
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第11期1268-1271,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 浙江省药学会医院药学科研专项基金项目(2010ZYY 13)
关键词 氯法齐明 耐多药肺结核 疗效 抗结核药物 Clofazimine Multi-drug-resist-ant Tuberculosis Efficacy Antituberculosisdrugs
  • 相关文献

参考文献10

  • 1Wright A, Zignol M, Van Deun A, et al. Epidemi ology of antituberculosis drug resistance 2002-07 an updated analysis of the Global Project on Anti Tuberculosis Drug Resistance Surveillance[J]. Lan- cet,2009, 373 (9678): 1861-1873.
  • 2唐神结.耐药结核病的综合治疗[J].中华临床医师杂志(电子版),2010,4(7):916-919. 被引量:13
  • 3Reddy VM, Nadahur G, Daneluzzi D, et al. Anti tuberculosis activities of clofazimine and its new an alogs B4154 and 4157[J]. Antimicrob Agents Che mother, 1996, 40(3): 633-636.
  • 4O'Connor R, O'Sullivan JF, O'Kennedy R. The pharmacology, metabolism, and chemistry of clofa- zimine[J]. Drug Metab Rev, 1995 , 27 ( 4 ) : 591- 614.
  • 5Reddy VM, O'Sullivan JF, Gangadharam PR. Anti- mycobactrial activities of riminophenazines [J]. J Antimicrob Chemother, 19 9 9, 4 3 (5): 615 - 6 2 3.
  • 6陆宇,郑梅琴,王彬,赵伟杰,李芃,初乃惠,梁博文.氯法齐明抗结核分枝杆菌的体内外活性研究[J].中华结核和呼吸杂志,2008,31(10):752-755. 被引量:23
  • 7Mukherjee .IS, Rich ML, Socci AR, et al. Pro- grammes and principles in treatment of multidrug- resistant tuberculosis [ J ]. Lancet, 2004, 363 (9407) : 474- 481.
  • 8Du Toit LC, Pillay V, Danckwerts MP. Tuberculo- sis chemotherapy., current drug delivery approaches [J]. RespirRes, 2006,7(1):118-136.
  • 9Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine[J]. Chest, 2003, 124(4) :1482-1486.
  • 10World Health Organization. Guidelines for the pro grammatic management of drug-resistant tuberculo sis: emergency update 2008[S]. Geneva: WHO 2008.

二级参考文献26

  • 1陆宇,王彬,郑梅琴,赵伟杰,李芃.应用Alamar Blue和MTT测定抗结核药物最低抑菌浓度的研究[J].中国防痨杂志,2007,29(6):499-501. 被引量:37
  • 2唐神结,肖和平.耐多药结核病的综合治疗[J].中华结核和呼吸杂志,2003,26(11):715-718. 被引量:64
  • 3Reddy VM, O' Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother,1999,43 : 615-623.
  • 4Jagannath C, Reddy MV, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med, 1995,151 : 1083-1086.
  • 5Ji B, Lounis N, Truffot-Pernot C, et al. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother, 1994,38: 2521-2529.
  • 6Adams LB, Sinha I, Franzblau SG, et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother, 1999,43 : 1638-1643.
  • 7Reddy VM, Nadadhur G, Daneluzzi D, et al. Antituberculosis activities of clofazimine and its new analogs B4154 and 134157. Antimicrob Agents Chemother, 1996,40:633-636.
  • 8Nix DE, Adam RD, Auclair B, et al. Phannacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) , 2004,84:365-373.
  • 9Jadhav MV, Sathe AG, Deore SS, et al. Tissue concentration, systemic distribution and toxicity of clofazimine-an autopsy study. Indian J Pathol Micmbiol,2004,47: 281-283.
  • 10O' Connor R, O' Sullivan JF, O' Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev, 1995, 27:591-614.

共引文献34

同被引文献208

引证文献20

二级引证文献514

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部